NOVEL USE OF SODIUM DICHLOROISOCYANURATE (NaDCC) AND A PHARMACEUTICAL FORMULATION PREPARED THEREFROM

Abstract

The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:

##STR00001##

for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

Claims

1. Use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure: ##STR00004## for the treatment and/or prevention of COVID-19 infection.

2. A pharmaceutical formulation comprising: a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide (NaDCC) having a particle size in the range of 3 μm to 7 μm; a first lactose having a particle size in the range of 15 μm to 120 μm; a second lactose having a particle size in the range of 1 μm to 70 μm; and at least one excipient; wherein the weight ratio of the first lactose to the second lactose is in the range of 4:1 to 10:1; wherein said first lactose and second lactose are adsorbed on said micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide (NaDCC); and wherein said pharmaceutical formulation is in the form of an inhalable dry powder.

3. The pharmaceutical formulation as claimed in claim 2, wherein said micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide is present in an amount in the range of 25 wt % to 65 wt % with respect to the total mass of the formulation.

4. The pharmaceutical formulation as claimed in claim 2, wherein said first lactose is present in an amount in the range of 25 wt % to 65 wt % with respect to the total mass of the formulation.

5. The pharmaceutical formulation as claimed in claim 2, wherein said second lactose is present in an amount in the range of 2 wt % to 15 wt % with respect to the total mass of the formulation.

6. The pharmaceutical formulation as claimed in claim 2, wherein said excipient is at least one selected from the group consisting of glacial acetic acid, cyanuric acid, citric acid, magnesium stearate, hydrophilic colloidal silica and L-Leucine.

7. The pharmaceutical formulation as claimed in claim 2, wherein the median mass aerodynamic diameter of said particles of inhalable dry powder is in the range of 2 μm to 5 μm.

8. The pharmaceutical formulation as claimed in claim 2, wherein the mean particle size (d10) of said first lactose is in the range of 19 μm to 43 μm.

9. The pharmaceutical formulation as claimed in claim 2, wherein the mean particle size (d50) of said first lactose is in the range of 53 μm to 66 μm.

10. The pharmaceutical formulation as claimed in claim 2, wherein the mean particle size (d90) of said first lactose is in the range of 75 μm to 106 μm.

11. The pharmaceutical formulation as claimed in claim 2, wherein the mean particle size (d10) of said second lactose is in the range of 1.4 μm to 3.3 μm.

12. The pharmaceutical formulation as claimed in claim 2, wherein the mean particle size (d50) of said second lactose is in the range of 10.9 μm to 24.9 μm.

13. The pharmaceutical formulation as claimed in claim 2, wherein the mean particle size (d90) of said second lactose is in the range of 32.6 μm to 60.4 μm.

14. The pharmaceutical formulation as claimed in claim 2, wherein said formulation has an antibacterial activity, wound healing activity and antifungal activity.

15. The pharmaceutical formulation as claimed in claim 2, wherein said formulation is used in the treatment and/or prevention of SARS COVID-19 infection, enveloped viruses, EBOLA virus, HIV, HBV, HCV, influenza virus, and MERS.

16. The pharmaceutical formulation as claimed in claim 2, wherein said formulation further comprise at least one anti-viral drug.

17. The pharmaceutical formulation as claimed in claim 16, wherein said anti-viral drug is selected from dexamethasone, Ivermectin, Favipiravir, Ribavirin, Lopinavir, Ritonavir, Remdesivir, Arbidol, Chloroquine, Hydroxychloroquine, Cyclosporin A, Interferons, and Tocilizumab.

18. The pharmaceutical formulation as claimed in claim 2, wherein said formulation is in a dosage form selected from solution, nasal spray, and hydrogel.

Description

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWING

[0029] The present disclosure will now be described with the help of the accompanying drawing, in which:

[0030] FIG. 1 illustrates an effective antibacterial activity and anti-fungal activity of NaDCC towards bacteria and fungus isolated from Salacia reticulata root extract;

[0031] FIG. 2 illustrates an effective antibacterial activity of NaDCC towards bacteria isolated from Garcinia cambogia fruit rind extract;

[0032] FIG. 3A and FIG. 3B illustrate the % inhibition of COVID-19 virus with respect to the reduction of replication of virus and enhancement of mammalian cell vero6 survival (cytotoxicity) respectively;

[0033] FIG. 4 illustrates an efficacy of NaDCC towards the inhibition of ACE2 receptor;

[0034] FIG. 5A illustrates effect of NaDCC dry powder inhaler on Lung Total Protein (mg/dL) level;

[0035] FIG. 5B illustrates effect of NaDCC dry powder inhaler on Lactate Dehydrogenase activity (U/L) level;

[0036] FIG. 5C illustrates effect of NaDCC dry powder inhaler on BALF PMN Neutrophil count;

[0037] FIG. 5D illustrates effect of NaDCC dry powder inhaler on BALF Macrophages count;

[0038] FIG. 5E illustrates effect of NaDCC dry powder inhaler on BALF Lymphocytes count;

[0039] FIG. 5F illustrates effect of NaDCC dry powder inhaler on BALF Eosinophils count;

[0040] FIG. 6A illustrates effect of NaDCC dry powder inhaler on Histopathology of Lung via transverse section; and

[0041] FIG. 6B illustrates effect of NaDCC dry powder inhaler on Histopathology of Lung via cross-section.

DETAILED DESCRIPTION

[0042] Embodiments, of the present disclosure, will now be described with reference to the accompanying drawing.

[0043] Embodiments are provided so as to thoroughly and fully convey the scope of the present disclosure to the person skilled in the art. Numerous details are set forth, relating to specific components, and methods, to provide a complete understanding of embodiments of the present disclosure. It will be apparent to the person skilled in the art that the details provided in the embodiments should not be construed to limit the scope of the present disclosure. In some embodiments, well-known processes, well-known apparatus structures, and well-known techniques are not described in detail.

[0044] The terminology used, in the present disclosure, is only for the purpose of explaining a particular embodiment and such terminology shall not be considered to limit the scope of the present disclosure. As used in the present disclosure, the forms “a,” “an,” and “the” may be intended to include the plural forms as well, unless the context clearly suggests otherwise. The terms “comprises,” “comprising,” “including,” and “having,” are open ended transitional phrases and therefore specify the presence of stated features, integers, steps, operations, elements, modules, units and/or components, but do not forbid the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The particular order of steps disclosed in the method and process of the present disclosure is not to be construed as necessarily requiring their performance as described or illustrated. It is also to be understood that additional or alternative steps may be employed.

[0045] Coronaviruses are a large family of viruses that cause illness in humans and animals.

[0046] The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:

##STR00003##

[0047] for a treatment and/or prevention of COVID-19 infection.

[0048] NaDCC has been shown to be an effective antimicrobial agent and anti-COVID agent. The capacity of NaDCC to continue to release significant amounts of HOCl allows it to operate over a wider pH range.

[0049] NaDCC produces hypochlorous acid, a well-known oxidizing agent.

NaOCl+H.sub.2O.fwdarw.HOCl+NaOH

[0050] Sodium Hypochlorite Dispersion in Water

NaCl.sub.2(NCOI).sub.3+2H.sub.2O.fwdarw.22HOCl+NaH.sub.2(NCOI).sub.3

[0051] NaDCC Dissolution in Water

[0052] NaDCC has a shelf life of 5 years in temperate and tropical climates. The antimicrobial activity of NaDCC is independent of pH and temperature, and is found to be effective on 29 Gram-positive and 29 Gram-negative bacteria, as well as 66 fungi. The use of NaDCC has been recommended for washing of vegetables, fruits and other edible items and above all in disinfecting feeding Bottles and teats. NaDCC at a concentration of 25 mg/ml removed all coliforms and E. coli from low turbidity water by 1.8-2.8 logs of viable bacteria from raw river water. Bacterial membrane disruption and release of cell contents is not observed at concentrations below 5 mM HOCl.

[0053] In an embodiment, the present disclosure further relates to pharmaceutical a formulation comprises: [0054] a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a particle size in the range of 3 μm to 7 μm; [0055] a first lactose having a particle size in the range of 15 μm to 120 μm; [0056] a second lactose having a particle size in the range of 1 μm to 70 μm; and [0057] at least one excipient.

[0058] In an embodiment, the micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide (NaDCC) is in an amount in the range of 25 wt % to 65 wt % with respect to the total weight of the formulation.

[0059] In an embodiment, the first lactose is in an amount in the range of 25 wt % to 65 wt % with respect to the total weight of the formulation.

[0060] In an embodiment, the mean particle size (d10) of the first lactose is in the range of 19 μm to 43 μm.

[0061] In an embodiment, the mean particle size (d50) of the first lactose is in the range of 53 μm to 66 μm.

[0062] In an embodiment, the mean particle size (d90) of the first lactose is in the range of 75 μm to 106 μm.

[0063] In an embodiment, the first lactose is respitose SV003.

[0064] In an embodiment, the second lactose is in an amount in the range of 2 wt % to 15 wt % with respect to the total weight of the formulation.

[0065] In an embodiment, the mean particle size (d10) of the second lactose is in the range of 1 μm to 4 μm.

[0066] In an embodiment, the mean particle size (d50) of the second lactose is in the range of 10 μm to 25 μm.

[0067] In an embodiment, the mean particle size (d90) of the second lactose is in the range of 30 μm to 65 μm.

[0068] In an embodiment, the second lactose is respitose ML006.

[0069] In an embodiment, a weight ratio of the first lactose to the second lactose is in the range of 4:1 to 10:1.

[0070] In an embodiment, at least one excipient is in an amount in the range of 20 wt % to 80 wt % with respect to the total weight of the formulation.

[0071] In an embodiment, the excipient is selected from glacial acetic acid, cyanuric acid, citric acid, magnesium stearate, hydrophilic colloidal silica such as AEROSIL 200, L-Leucine.

[0072] In an embodiment of the present disclosure, citric acid, magnesium stearate, hydrophilic colloidal silica such as AEROSIL 200 and L-Leucine acts as dispersibility enhancers which is added to NaDCC DPI that targets higher concentration of NaDCC in the fine particle fraction (FPF) of NaDCC DPI. The dispersibility enhancer will also prevent coagulation disorders that is commonly found in COVID-19 patients.

[0073] In an embodiment, the first lactose and the second lactose are adsorbed on the surface of the micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide (NaDCC).

[0074] The lactose used in the present disclosure is well-known which is used as a carrier to distribute the actives during inhalation.

[0075] In an embodiment, the pharmaceutical formulation is administered to the subject via inhalation route in the form of dry powder inhalation.

[0076] In an exemplary embodiment, the pharmaceutical formulation is administered to the subject via inhalation route in the form of dry powder inhalation using pressurized metered-dose inhalation, unit-dose device, multiple unit-dose device, and reservoir device.

[0077] In an embodiment, the median mass aerodynamic diameter (MMAD) of the pharmaceutical formulation in the form of dry powder inhalation is in the range of 2 μm to 5 μm.

[0078] In an embodiment, the lung to plasma ratio of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide is in the range of 25 to 50 wt %.

[0079] In an embodiment, the formulation has an antibacterial activity, wound healing activity and antifungal activity.

[0080] The pharmaceutical formulation is used in the treatment and/or prevention of SARS COVID-19 infection and other viruses such as enveloped viruses, EBOLA virus, HIV, HBV, HCV, influenza virus, and MERS.

[0081] In an embodiment, the pharmaceutical formulation further comprise at least one anti-viral drug.

[0082] In an embodiment, the anti-viral drug is selected from the dexamethasone, Ivermectin, Favipiravir, Ribavirin, Lopinavir, Ritonavir, Remdesivir, Arbidol, Chloroquine, Hydroxychloroquine, Cyclosporin A, Interferons, and Tocilizumab.

[0083] In an embodiment, the pharmaceutical formulation is in a dosage form selected from dry powder, solution, nasal spray, and hydrogel.

[0084] In an embodiment, the pharmaceutical formulation of the present disclosure, is stabilized in various forms and can be stored at room temperature (ambient to 37° C.).

[0085] In another embodiment, the present disclosure still further discloses sodium dichioroisocyanurate for disinfecting damaged or affected mammalian tissue, including wounds and burns; disinfecting or cleansing surfaces; and treating food products and herbal extracts along with preservation of consumable products for human consumption.

[0086] In an embodiment, the wound healing solution comprises a predetermined amount of NaDCC, lime splash as a fragrance, and water.

[0087] In another embodiment, the wound healing hydrogel comprises a predetermined amount of NaDCC, Carbopol, water, and lime splash.

[0088] In another aspect of the present disclosure, there is provided a process for the preparation of the pharmaceutical formulation in the form of dry powder inhalation.

[0089] The process is described in detail.

[0090] In a first step, a first lactose and a second lactose are blended to obtain the lactose mixture. The lactose mixture is sifted through 80 mesh in a controlled temperature and humidity conditions to obtain a homogeneous lactose mixture.

[0091] In a second step, excipient is sifted through 80 mesh and mixed with the homogenous lactose mixture to obtain a resultant mixture.

[0092] In a third step, separately, NaDCC is sifted through 80 mesh and blended with the resultant mixture at 15 RPM for 20 mins to obtain a pharmaceutical formulation in the form of dry powder inhalation (DPI).

[0093] The so obtained pharmaceutical formulation is loaded into size 3 HPMC (Hydroxypropyl methylcellulose) capsules using a capsule filler.

[0094] In another embodiment of the present disclosure, there is provided a stable NaDCC formulation with the use of micronized excipients such as mannitol, trehalose, sorbitol, dextrose at ratios of 20 to 80% in place of lactose. Since mannitol rehydrates mucus and changes the properties of bronchi walls, that acts to enhance airway clearance by improving interaction between cilia and mucus. It is beneficial for treatment of viral diseases affecting the lungs. Trehalose, a nonreducing sugar, can efficiently improve dry powder aerosolization by increasing the FPF and has distinguished similarities to the pulmonary sugar carrier, lactose monohydrate, as both are crystalline disaccharides and both are hydrates.

[0095] The foregoing description of the embodiments has been provided for purposes of illustration and not intended to limit the scope of the present disclosure. Individual components of a particular embodiment are generally not limited to that particular embodiment, but, are interchangeable. Such variations are not to be regarded as a departure from the present disclosure, and all such modifications are considered to be within the scope of the present disclosure.

[0096] The present disclosure is further described in light of the following experiments which are set forth for illustration purpose only and not to be construed for limiting the scope of the disclosure. The following experiments can be tested to scale up to industrial/commercial scale and the results obtained can be extrapolated to industrial scale.

EXPERIMENTAL DETAILS

Example 1: Preparation of Dry Powder Inhalation of Sodium Dichloroisocyanurate in Accordance with the Present Disclosure

[0097] 7.5 g of micronized NaDCC, 4.5 g Respitose SV003 IP, and 0.5 g Respitose ML006 USP NF were weighed. All the materials were passed through the sieve no. 80 and mixed properly to obtain a dry powder formulation comprising NaDCC, respitose SV003 IP and respitose ML6 USP. The dry powder formulation comprising NaDCC, respitose SV003 IP and respitose ML006 USP were filled in HPMC (hydroxylpropyl methylcellulose) based, non-stick, and reddish brown/transparent capsule having size of 3.

TABLE-US-00001 TABLE 1 NaDCC Dry powder for inhalation After mg/ Calculation Mixing Capsule % Formulation qty in gm. (gm.) Micronized 15 60 7.5 7.5 (NaDCC) Respitose 9 36 4.5 4.5 SV003 IP (first lactose) Respitose 1 4 0.5 0.5 ML006 USP NF (Second lactose) Total weight of 25 100 12.5  12.5  the powder HPMC, non-stick, 1 No. 500 No. 500 No. Reddish Brown/ Transparent capsule, Size 3

Example 2

[0098] The dry powder inhalation formulations were prepared in the similar manner as described in Example 1, by varying the concentration of ingredients/components as tabulated in Table 2:

TABLE-US-00002 TABLE 2 NaDCC Dry powder for inhalation After mg/ Calculation Mixing Capsule % Formulation qty in gm. (gm.) Micronized 7 28 3.5 3.5 (NaDCC) Respitose 15.5 62 7.75 7.75 SV003 IP (first lactose) Respitose 2.5 10 1.25 1.25 ML006 USP NF (second lactose) Total weight of 25 100 12.5 12.5 the powder HPMC, non-stick, 1 No. 500 No. 500 No. Reddish Brown/ Transparent capsule, Size 3

TABLE-US-00003 TABLE 3 NaDCC DPI 7 mg Sr. No. Ingredient Mg/Capsule Analysis 1 3NC (Micronized 7.00 Assay: NaDCC) 98.12% 2 Syloid FP244 IH 1.3750 (colloidal silica) 3 Respitose SV003 USP 14.125 NF (first lactose) 4 Respitose ML006 2.500 USPNF (second lactose) Total weight 25 5 HPMC, Size “3”, Non- 1.0 No. stick, Red trans/Trans cap

Example 3: NaDCC DPI—Stability Study

[0099] The stability conditions of NaDCC DPI are illustrated below in Table 4.

TABLE-US-00004 TABLE 4 Stability Result Product Name: NaDCC DPI 7 mg Batch Size: 1000 capsules Tests Description Assay T0 T1 T2 Limit *** 90-110%  Pack 1: Initial *** 106.2%  Not Done HDPE Composite bottle Assay 1M/2-8 *** 100.5%  1M/25/60% *** 97.3% 1M/30/75% *** 95.4% 1M/40/75% *** 49.8% 3M/2-8 *** 102.3%  10.6% 60.9% 29.420% 3M/25/60% *** 96.0% 10.6% 56.4% 20.840% 3M/30/75% *** 81.9% 9.0% 51.1% 16.750% 3M/40/75% ***  3.1% Not done *** White to off white powder

[0100] Inference: The dry powder inhalation (DPI) formulation of NaDCC in capsules of the present disclosure was subjected to 1 and 3 months stability testing at 25° C./60% RH and 40° C./75% RH respectively. It is evident from table 4 that NaDCC (API) is stable for a longer period of time, at 25° C./60% RH, and 40° C./75% RH conditions as there was no change in the NaDCC content in dry powder inhalation (DPI) formulations of NaDCC 7 mg.

[0101] The so obtained dry powder inhalation formulation was filled into a size 3 HPMC capsule using a capsule filler.

[0102] Further, the so obtained NaDCC DPI was clinically assessed by determining the amount of cyanuric acid in the tissues.

[0103] Cyanuric acid was not detected in the lung homogenate samples of control animals and test animals' samples. However, in the test sample, cyanuric acid was seen at 0.004% by HPLC. This reflects that NaDCC was metabolized fast with a short half-life and not accumulated in tissues in the amount administered as a DPI. Free available chlorine by titrimetry method also not detected in any sample tested from the study confirming the results of cyanuric acid estimation. The inhaled NaDCC appears to be extensively metabolized and therefore be well tolerated in the chronic treatment of asthma and other chronic lung infections.

Example 4: % Microbial Load Reduction in Ayurvedic Herbs and Extracts by Using Sodium Dichloroisocyanurate (NaDCC)

[0104]

TABLE-US-00005 TABLE 5 Total % microbial S.N. Batch Parameter cfu/g reduction 1 RDP/SR/ Untreated 21000 Not 011903 applicable 2 RDP/SR/073 10 g of Salacia extract is <10 >99% mixed with 0.02 g of reduction NaDCC (0.2.% of input extract) and triturate well in mortar and pestle to get fine powdered extract. 3 RDP/SR/074 10 g of Salacia extract is <10 >99% mixed with 0.04 g of reduction NaDCC (0.4% of input extract) and triturate well in mortar and pestle to get fine powdered extract.

[0105] Inference: From the table 5 it is evident that, sodium dichioroisocyanurate (NaDCC) in an amount in the range of 0.05% to 5% when mixed with Salacia extract shows antibacterial activity and can reduce the bacterial load by 99.99% (which is 4 logs reduction in bacterial counts).

Example 5: Antibacterial and an Antifungal Activity of Sodium Dichloroisocyanurate (NaDCC) in Accordance with the Present Disclosure

[0106] The bacteria (Bacillus licheniformis, and Bacillus paralicheniformis) and fungus (Aspergillus sps) isolated from the Salacia reticulata and bacteria Bacillus licheniformis isolated from Garcinia cambogia extract was tested for susceptibility for the sensitivity towards NaDCC.

[0107] FIG. 1 illustrated an effective antibacterial activity and anti-fungal activity of NaDCC towards bacteria and fungus isolated from Salacia reticulata; and

[0108] FIG. 2 shows illustrated an effective antibacterial activity of NaDCC towards bacteria isolated from Garcinia cambogia extract.

Example 6: Anti-COVID Activity of Sodium Dichloroisocyanurate (NaDCC) as Per the Present Disclosure

[0109] FIG. 3A and FIG. 3B clearly indicated that NaDCC effectively reduce the replication of virus and increase the survival of cell. At 600 ppm concentration, NaDCC shows greater than 99.99% inhibition of the virus replication.

Example 7: Wound Healing Activity of Sodium Dichloroisocyanurate (NaDCC) in Dogs and Cats in Accordance with the Present Disclosure

[0110]

TABLE-US-00006 TABLE 6 Batch using acetic acid for stability studies NaDCC Solution Ingredient mg/ml % ml Batch size 200 3NC (NaDCC) 1.670 0.167 0.348 Acetic acid 998.33 99.833 qs Total 1 100 200

TABLE-US-00007 TABLE 7 Stability of the NaDCC in the solution: Product Name: NaDCC Solution Batch Size: 200 ml Available Description Chlorine Limit *** mg/ml pH HDPE bottle Initial *** 0.954 1.28 HDPE bottle 1 Month 2-8 *** 0.801 0.51 1 Month 25/60 *** 0.922 0.52 1 Month 40/75 *** 0.563 0.57 *** Clear colourless solution filled in 30 cc HDPE bottle

TABLE-US-00008 TABLE 8 Batch using acetic acid + cyanuric acid for stability studies Ingredient mg/ml % ml Batch size 200 NaDCC 1.670 0.167 0.348 Cyanuric acid 0.100 0.01 0.020 Acetic acid qs to 1 ml qs qs Total 1 100 200

TABLE-US-00009 TABLE 9 Stability data report: Product Name: NaDCC Solution Batch Size: 200 ml Available Description Chlorine Limit *** mg/ml pH HDPE bottle Initial *** 1.003 1.30 HDPE bottle 1 Month 2-8 *** 0.702 0.7 1 Month 25/60 *** 0.921 0.75 1 Month 40/75 *** 0.521 0.72 *** Clear colourless solution filled in 30 cc HDPE bottle

[0111] Inference:

[0112] From the tables 6 to 9 it is evident that, the Sodium dichloroisocyaniurate (NaDCC) is stable in acetic acid and cyanuric acid as a solution and can be used as a wound healing agent in cats and dogs with an appropriate dilutions of the solution (1% to 5% working solution to be made by freshly diluting with water). The stability studies indicate the level of residual free chlorine, which is the active ingredient for wound healing.

[0113] Further, it is also noted that commercially known product such as Microdacyn has wound healing activity due to the presence of hypochlorous acid (one molecule of HOCl) in the formulation. Therefore, NaDCC formulation has enhanced wound healing activity as upon hydrolysis NaDCC formulation results in the formation of two molecules of HOCl (which has wound healing activity).

Example 8: Efficacy of Sodium Dichloroisocyanurate (NaDCC) on Angiotensin-Converting Enzyme 2 (ACE 2) Receptor in Accordance with the Present Disclosure

[0114] The Angiotensin-converting enzyme 2, or ACE2 “receptor” is the protein that provides the entry point for the coronavirus to hook into and infect a wide range of human cells. ACE2 has been also proved to be the receptor for the human respiratory coronavirus NL63, the SARS-coronavirus (SARS-CoV) and the novel coronavirus 2019-nCoV/SARS-CoV-2. The ACE2/Spike inhibition assay allows screening of the potential inhibitors or candidates that can inhibit the interactions between the two targets namely inhibitor and the receptor which results in inhibition of entry of the virus. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection.

[0115] NaDCC at various concentrations keeping the peptide DX600 as a positive control using the ACE2 assay kit (BPS #79923) that comes in a convenient 96-well format, with purified ACE2, its substrate, and ACE2 buffer for 96 reactions were tested in the assay. The exopeptidase activity of the ACE2 was measured by the appearance of the fluorescence from the hydrolysis of the florigenic substrate.

[0116] FIG. 4 illustrates that the NaDCC effectively inhibits the ACE2 receptor assay at a concentration in the range of 10 mg/ml to 312 μg/ml that amounts to 3.5 to 7 μM. Hence, from the FIG. 4, it is evident that the mode of action of the inhibition of Covid-2 replication by NaDCC is through the inhibition of binding of the spike protein of the virus with the ACE2 receptor present in the host system.

Example 9: Toxicological Studies of NaDCC Dry Powder Inhaler (DPI)

[0117] Objectives: [0118] 1. To study the effect of NaDCC dry powder inhaler on lungs and Bronchioalveolar lavage fluid. [0119] 2. To study the effect of withdrawal after administration of NaDCC dry powder inhaler on lungs and Bronchioalveolar lavage fluid.

[0120] Materials:

[0121] Wistar Abino Rats of either sex weighing between 200 to 250 g was procured from Global Bioresearch Solutions Pvt Ltd., Pune.

[0122] Methods:

[0123] Healthy wistar rats of either sex (200-250 g) were purchased from the CPCSEA registered vendor, Pune. Animals were housed under a controlled environmental condition (25±2° C., 12 h dark-light cycle) with free access to pellet diet (Nutri Vet Life Science, India) and water before experiments. During this adaptation phase, the health status of the rats was supervised daily.

[0124] Healthy wistar rats (200-250 g) of either sex were divided into two groups such as control and NaDCC DPI treated groups. Ten rats of each sex were assigned to NaDCC DPI while 6 rats of each sex were assigned to Control group. Each animal was given accurate conditioning session for acclimation to the fabricated inhalation apparatus. The animals were dosed with NaDCC DPI using fabricated nose only inhalational chamber for one day. After 24 h, based on the observation, the animals were dosed with NaDCC DPI for 4 more days. At the end of 5.sup.th day, 5 rats of each sex were sacrificed and the lungs were isolated. The broncho alveolar lavage fluid (BALF) of the right lung was subjected to assay of LDH, total protein and total and differential WBC count while the left lung was used for histopathology. The drug free period of 3 days was given to the remaining animals. They were sacrificed and the left and right lungs were used for histopathology and biochemical, total and differential WBC counts, respectively. The same procedure was followed for control group of animals, except they were administered with air instead of dry powder inhalation of NaDCC.

[0125] Preparation and Administration of Doses:

[0126] One capsule of NaDCC dry powder inhaler prepared in accordance with the present disclosure containing 7 mg of NaDCC, was administered to one animal using the fabricated nose only inhalational chamber. The fabricated apparatus was used for complete fluidization of formulation allowing the natural nasal inhalation. The fabrication of apparatus was carried out as per the previous reported work. The formulation (capsule content) was placed in the cap and delivery port was covered by cotton wool. The fluidization was carried out for 4 min. The dose administered in animals was 28 mg/kg. Hence, the dose for human is 28×0.78-21.84 mg.

[0127] Results:

[0128] Effect of NaDCC Dry Powder Inhaler on Lung Total Protein (Mg/dL) Level

[0129] The total protein levels in the control groups were found between 74 and 77 mg/dL. Treatment with NaDCC dry powder inhaler in male animals did not cause any significant change of the total protein level in the lung when compared to the control male animals. Treatment with NaDCC dry powder inhaler did not also cause any change of the total protein level in lung in female animals when compared to the control female animals as tabulated in table 10 and FIG. 5A. Hence, upon withdrawal of treatment also, there was no significant change observed in NaDCC dry powder inhaler treated groups when compared to the respective control groups of animals.

[0130] Effect of NaDCC Dry Powder Inhaler on Lactate Dehydrogenase Activity (U/L) Level

[0131] The lactate dehydrogenase level in the control groups were found between 91 and 96 U/L. Treatment with NaDCC dry powder inhaler in male animals did not cause any significant change in lactate dehydrogenase activity when compared to control male animals. Treatment with NaDCC did not also cause any change in lactate dehydrogenase activity in female animals when compared to the control female animals as tabulated in table 10 and FIG. 5B. Hence, upon withdrawal of treatment also, there was no significant change observed in NaDCC dry powder inhaler treated groups when compared to the respective control groups of animals.

[0132] Effect of NaDCC Dry Powder Inhaler on BALF PMN Neutrophil Count

[0133] The BALF PMN Neutrophil in the control groups were found between 3 and 4. Treatment with NaDCC dry powder inhaler in male animals did not cause any significant change in BALF PMN neutrophils count when compared to control male animals. Treatment with NaDCC dry powder inhaler did not also cause any change in BALF PMN neutrophils count in female animals when compared to control female animals as tabulated in table 10 and FIG. 5C. Hence, upon withdrawal of treatment also, there was no significant change observed in NaDCC dry powder inhaler treated groups when compared to the respective control groups of animals.

[0134] Effect of NaDCC Dry Powder Inhaler on BALF Macrophages Count

[0135] The BALF Macrophages in the control groups were found between 528 and 556.

[0136] Treatment with NaDCC dry powder inhaler in male animals did not cause any significant change in BALF macrophages count when compared to the control male animals. Treatment with NaDCC dry powder inhaler did not also cause any change in BALF macrophages count in female animals when compared to the control female animals as tabulated in table 10 and FIG. 5D. Hence, upon withdrawal of treatment also, there was no significant change observed in NaDCC dry powder inhaler treated groups when compared to the respective control groups of animals.

[0137] Effect of NaDCC Dry Powder Inhaler on BALF Lymphocytes Count

[0138] The BALF Lymphocytes in the control groups were found between 2 and 3. Treatment with NaDCC dry powder inhaler in male animals did not cause any significant change in BALF lymphocytes count when compared to control male animals. Treatment with NaDCC did not also cause any change in BALF lymphocytes count in female animals when compared to the control female animals as tabulated in table 10 and FIG. 5E. Hence, upon withdrawal of treatment also, there was no significant change observed in NaDCC dry powder inhaler treated groups when compared to the respective control groups of animals.

[0139] Effect of NaDCC Dry Powder Inhaler on BALF Eosinophils Count

[0140] The BALF Eosinophils in the control groups were found to be between 0 and 1. Treatment with NaDCC dry powder inhaler in male animals did not cause any significant change in BALF eosinophils count when compared to the control male animals. Treatment with NaDCC dry powder inhaler did not also cause any change in BALF eosinophils count in female animals when compared to the control female animals as tabulated in table 10 and FIG. 5F. Hence, upon withdrawal of treatment also, there was no significant change observed in NaDCC dry powder inhaler treated groups when compared to the respective control groups of animals.

[0141] Effect of NaDCC Dry Powder Inhaler on Lung Histopathology

[0142] The treatment with NaDCC did not alter the lung architecture and alveoli. This was evident by the transverse section of FIG. 6A and cross sections of FIG. 6B of the male NaDCC dry powder inhaler treated animals and female NaDCC dry powder inhaler treated animals as compared to the respective control animals.

TABLE-US-00010 TABLE 10 Effect of NaDCC DPI on Lung and Bronchioalveolar Lavage Fluid Parameters Parameter Control (n = 3) NaDCC DPI (n = 5) Parameters After Male Female Male Female Total Proteins Treatment 77.00 ± 4.51 74.00 ± 2.31 75.00 ± 3.11 75.60 ± 3.04 (mg/dL) Withdrawal 75.33 ± 3.53 74.00 ± 1.53 73.40 ± 2.77 75.20 ± 2.52 LDH activity Treatment 96.33 ± 6.64 91.67 ± 4.98 94.00 ± 2.03 91.00 ± 1.95 (U/L) Withdrawal 96.67 ± 5.49 94.33 ± 3.84 95.20 ± 1.69 91.40 ± 0.93 Number of PMN Treatment  3.67 ± 0.88  4.00 ± 1.16  3.60 ± 0.75  3.20 ± 0.80 Neutrophils Withdrawal  4.67 ± 0.88  4.67 ± 0.33  4.20 ± 0.49  4.00 ± 0.71 Number of Treatment 556.30 ± 41.07 544.00 ± 19.01 540.20 ± 23.12 528.00 ± 29.87 Macrophages Withdrawal 570.00 ± 41.68 559.00 ± 21.13 553.40 ± 20.62 522.80 ± 22.11 Number of Treatment  2.67 ± 0.33  3.00 ± 0.58  2.60 ± 0.40  2.80 ± 0.58 Lymphocytes Withdrawal  2.67 ± 0.33  3.00 ± 0.58  3.00 ± 0.32  2.60 ± 0.40 Number of Treatment  0.67 ± 0.33  0.67 ± 0.33  0.60 ± 0.24  0.60 ± 0.24 Eosinophils Withdrawal  0.67 ± 0.33  0.67 ± 0.33  0.60 ± 0.24  0.60 ± 0.24

[0143] Inference:

[0144] From table 10 it is evident that the administration of dry powder inhaler of NaDCC for 5 days did not cause any change in the male or female animals in the total proteins, lactate dehydrogenase activity, bronchioalveolar lavage fluid-neutrophils, macrophages, lymphocytes or eosinophils as compared to these parameters in control male and control female animals.

[0145] NaDCC dry powder inhalation did not change the total protein level, lactate dehydrogenase level in lung tissues which confirm that there is no tissue damage in lung due to administration. There were no changes in neutrophils, macrophages, lymphocytes or eosinophils confirming the lack of inflammatory changes.

[0146] Based on the above findings, it was concluded that NaDCC dry powder inhaler did not have toxicity in acute inhalational toxicity test conducted for 5 days. Therefore, the human equivalent dose of NaDCC dry powder inhaler 21.84 mg did not cause any toxicity upon inhalation and is safe to be administered to human.

[0147] Technical Advancements

[0148] The present disclosure described herein above has several technical advantages including, but not limited to, the realization of, NaDCC is: [0149] effective against COVID-19 virus, biologically compatible, stable, efficient, economic, non-cytotoxic, and non-allergic; [0150] is used as a disinfectants for many purposes including wound cleansing, hospital use, water disinfection for human consumption and swimming pool disinfection; [0151] is used as a teat dip or spray prior to or after milking topically; [0152] less toxic in terms of teratogenicity and embryotoxicity.

[0153] Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising, will be understood to imply the inclusion of a stated element, integer or step,” or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0154] The use of the expression “at least” or “at least one” suggests the use of one or more elements or ingredients or quantities, as the use may be in the embodiment of the invention to achieve one or more of the desired objects or results. While certain embodiments of the inventions have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of the inventions. Variations or modifications to the formulation of this invention, within the scope of the invention, may occur to those skilled in the art upon reviewing the disclosure herein. Such variations or modifications are well within the spirit of this invention.

[0155] The numerical values given for various physical parameters, dimensions and quantities are only approximate values and it is envisaged that the values higher than the numerical value assigned to the physical parameters, dimensions and quantities fall within the scope of the invention unless there is a statement in the specification to the contrary.

[0156] While considerable emphasis has been placed herein on the specific features of the preferred embodiment, it will be appreciated that many additional features can be added and that many changes can be made in the preferred embodiment without departing from the principles of the disclosure. These and other changes in the preferred embodiment of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.